[ad_1]
Health
AFP
Mehdi Fedouach
Emoji picture
Public assistance: Hopitaux de Paris, the French organization, has announced that doctors have received positive results from the use of medicines to treat rheumatoid arthritis, in the treatment of patients with COVID-19.
Read more
“In people with COVID-19 infected with pneumonia, the ‘cytokine storm’ caused by an immune system disorder is believed to lead to severe respiratory failure and possibly death. The CORIMUNO-19 platform is rapidly prepared to assess the Efficacy and Tolerance of Many Rates Immunology and other therapies in adult patients with severe COVID-19 infection with a series of randomized, multi-center trials beginning on March 27, 2020. “
The results of this randomized controlled trial with an open multicenter designation of tosilizumab relate to a monoclonal antibody that blocks interleukin-6 cytokine receptors, which is used clinically in particular in the treatment of rheumatoid arthritis.
Patients who underwent this trial were selected based on their history of hospital admission for moderate or severe pneumonia from COVID-19, but they do not require intensive care. The need to ventilate the lungs (non-gaseous or mechanical) or die after 14 days was approved as a failure of the experiment.
129 patients were randomized to this trial, 64 of whom were traditionally treated and 65 treated with tocilizumab. A significantly lower percentage of patients achieved the end result in the tocilizumab group.
The “cytokine storm” is the reaction of the immune system to an uncontrolled increase in cytokines, which are information molecules that stimulate cells to fight the virus that entered the body. As a result of its increased focus on the focus of inflammation, destruction begins not only in the inflamed tissues, but also in the tissues adjacent to them.
Source: Novosti
[ad_2]
